Global Access Initiative
Global Access Initiative is how Hologic delivers our world-class diagnostics to low- and middle-income countries. We forge partnerships around the world to empower local healthcare communities with the power of science.
Science in Service of All
Hologic innovations can't be contained in the lab. We are committed to finding new ways to share the science of sure with everyone.
Local Action. Global Impact.
We extend our spirit of innovation beyond the lab, adapting our solutions to local needs and delivering them to emerging markets. We expand our reach by integrating new diagnostic technologies and continually looking for ways to improve patient care. We further our commitment to a healthier future for all.
22,800,000
Lives Impacted1
Broad Assay
Menu
Viral load monitoring, cervical health, sexually transmitted infections, and respiratory health
100 and
Counting
Panther® instruments installed through Global Access Initiative
Key
Partnerships
Ministries of Health and bilateral and multilateral donor organizations
Pricing Reduced
by up to Half
Among all diagnostic suppliers generating over $236M in savings so far2
Global Reach
We imagine a future where access to quality healthcare knows no borders. We are working to build access to world-class diagnostics worldwide.
Latin America & Caribbean
- Bahamas
- Brazil
- Colombia
- Costa Rica
- Dominica
- Dominican Republic
- El Salvador
- Grenada
- Guatemala
- Guyana
- Haiti
- Honduras
- Jamaica
- Panama
- Saint Lucia
- Saint Vincent and the Grenadines
Africa & Middle East
- Botswana
- Eswatini
- Kenya
- Lesotho
- Mozambique
- Namibia
- Nigeria
- South Africa
- Tanzania (United Republic)
- Uganda
- Zambia
- Zimbabwe
- Algeria
- Angola
- Benin
- Burkina Faso
- Burundi
- Cabo Verde
- Cameroon
- Central African Republic
- Comoros
- Congo (ROC)
- Cote d'Ivoire
- Congo (Democratic Republic)
- Egypt
- Ethiopia
- Gambia
- Ghana
- Guinea
- Guinea-Bissau
- Iran (Islamic Republic)
- Iraq
- Jordan
- Lebanon
- Liberia
- Libya
- Malawi
- Mali
- Mauritania
- Morocco
- Palestine
- Rwanda
- Senegal
- Sierra Leone
- South Sudan
- Syrian Arab Republic
- Togo
- Tunisia
- Yemen
Europe & Central Asia
- Ukraine
- Armenia
- Azerbaijan
- Belarus
- Bhutan
- Georgia
- Kazakhstan
- Kyrgyzstan
- Moldova
- Mongolia
- Montenegro
- North Macedonia
- Romania
- Russian Federation
South & Southeast Asia
- Afghanistan
- Bangladesh
- Cambodia
- India
- Indonesia
- Laos (People's Democratic Republic)
- Malaysia
- Myanmar
- Nepal
- Pakistan
- Philippines
- Sri Lanka
- Thailand
- Timor-Leste
- Vietnam
Pacific
- Fiji
- Kiribati
- Marshall Islands
- Micronesia (Federated States)
- Papua New Guinea
- Samoa
- Solomon Islands
- Tonga
- Tuvalu
- Vanuatu
Powerful Diagnostics Scaled to Your Needs.
Panther Scalable Solutions offer excellent performance adapted to a laboratory's needs. A broad assay menu and multiplex testing put the power of world'class diagnostics at your fingertips.
- Full automation reduces hands-on time
- Continuous sample loading and rapid turnaround time
- Small footprint delivers more tests per square meter
Solutions
Building access to better care is more than building world-class instruments. We go the extra mile to expand access to our solutions .
Removing the Barriers to Diagnostics
The true cost of implementing a solution can vary drastically depending on the structure of the supply chain. Global Access Initiative implements our solutions using Delivered at Place (DAP) and Delivered Duty Paid (DDP) incoterms. These most expansive incoterms mean that we handle the logistics of getting your lab up and running, no matter where it is.
Source: iccwbo.org
All-Inclusive Includes It All
Our solutions are priced to include everything a lab needs to empower their local healthcare community. We are transparent about our real costs and what we include.
- We include service, maintenance, and initial and ongoing training in our packages.
- We are committed to high performance, standardizing our service package to deliver on 10 KPIs.
- We collaborate closely with our partners, routinely reviewing and improving on our reported KPIs.
First Do No Harm
We harness the power of transcription mediated amplification (TMA), a proven science that generates results with high accuracy and precision without generating hazardous liquid waste. By reducing the need for complicated waste disposal we reduce the barriers to care.
United Nations Sustainable Development Goals
We join in the UN Sustainable Development Goals' (SDG) vision of "peace and prosperity for people and the planet." Our capabilities and expertise are at work around the world in pursuit of SDG 3.3, 3.7 and 3.8.
Consolidate your assay menu
Global Access Initiative draws on Hologic's broad menu of assays to provide a portfolio tailored to the health challenges facing low- and middle-income countries.
An End to AIDS
We are committed to applying our expertise and capabilities to help countries achieve the UNAIDs 2030 goals of 95% of people knowing their status, 95% of people living with HIV receiving treatment and 95% of those receiving treatment virally suppressed.3
- Our Aptima® HIV Quant Dx assay is WHO prequalified.
- Dried blood spot (DBS) specimens are the only viable options for some patients.
- The Aptima HIV-1 Quant Dx assay is WHO prequalified for DBS bringing more testing to more people. The Aptima HIV-1 Quant Dx assay can be use for both viral load monitoring and Early Infant Diagnosis (EID).
Supporting the Cure
Hepatitis C virus (HCV) infection is often comorbid with HIV infection. We are working to make the cure for HCV more accessible through diagnostics.
- Aptima® HCV Quant Dx is a powerful tool for achieving the WHO HCV goals of 90% of infections diagnosed and 80% cured by 2030.4
- Our Aptima® HCV Quant Dx assay is dual claim, delivering the diagnostic and monitoring capabilities providers need to cure this infection.
- We are committed to assisting the Hepatitis Fund in their global mission to boost financial and political support for the ellimination of hepatitis.
Enabling Care
We are committed to building access to the diagnostics essential for mitigating the harm of hepatits B virus (HBV) infection.
- Aptima® HBV Quant is helping providers working toward the WHO HBV goals of 90% of infections diagnosed and 80% treated by 2030.4
- Our Aptima® HBV Quant assay delivers the viral load monitoring capability that providers need to successfully treat HBV infection.
- We are committed to assisting the Hepatitis Fund in their global mission to boost financial and political support for the ellimination of hepatitis.
Standing Up to Cervical Cancer
Human papillomavirus (HPV) infection is the cause of 99% of cervical cancers.5 Detection of HPV infection is vital to providing life-saving surveillance and care.
- The Aptima HPV assay is vital in achieving the WHO goals of 70% of women screened for cervical cancer by age 35 and 90% of cervical cancers treated by 2030.6
- Women living with HIV are six times more likely to develop cervical cancer.6
- Our Aptima® HPV assay enables providers to identify women at risk of cervical cancer so they can receive the protection of further care.
FAQs
The all-inclusive testing price consists of all supplies and services needed to generate a patient result, including: instrument placement, reagents and consumables, service and maintenance, and freight and logistics.
The all-inclusive testing price does not include ancillary costs, for example those associated with sample collection, sample transport, laboratory staff time, laboratory infrastructure, generic lab supplies (e.g. primary collection tubes, disposable gloves, bleach, bleach bottles, bleach enhancer, waste bottles, etc.), inventory management or general administration and overhead costs. The all-inclusive testing price does not include the following additional equipment necessary to run the tests: centrifuge, vortex mixer and pipettor.
Any organization or entity that is purchasing testing services on behalf of public-sector patients in the eligible countries, including procurement agents, government agencies, non-governmental organizations (NGOs) and similar organizations.
Countries were selected based on burden of disease, qualification as a lower- or middle-income country (based on WHO and World Bank criteria) and ability for Hologic (and partners) to engage in commercial activity [e.g., political stability, appropriate infrastructure, qualified local agent for representation, country regulatory status for the relevant assay(s) (i.e., is local regulatory approval or registration required), etc.].
Depending on laboratory infrastructure, the Panther system is appropriate for Tier 5 (reference laboratories), Tier 4 (central hospital laboratories) and even some Tier 3 (provincial hospital laboratories) facilities.
Each testing site must meet the following minimum infrastructure requirements: a) floor space to accommodate an instrument with dimensions 122 cm (width) x 81.5 cm (depth) x 175 cm (height), b) bench or tabletop space to accommodate a rocker and centrifuge, c) an electrical connection that can support up to a 1400W draw and a dedicated 20-amp circuit, d) a backup generator capable of supporting all of the equipment, e) central or wall-mounted air conditioning with adequate capacity to maintain an ambient temperature between 15°C and 30°C in the laboratory space (and relative humidity between 20% and 85%), f) a sink or washbasin for disposal of liquid waste, g) access to one or more refrigerators with temperature control (2°C – 8°C) to store patient samples and assays corresponding to the expected throughput, and h) access to one or more freezers with temperature control (-15°C to -35°C) to store calibrators and controls corresponding to the expected throughput. Hologic will provide a UPS and surge protector but shall not bear any costs associated with renovations or infrastructure upgrades.
The Panther system is a fully-automated, sample-to-result instrument. With consumables and reagents loaded, up to 120 samples can be processed with no user intervention, providing complete walkaway automation. Hands-on time consists of reagent preparation, sample loading, reagent loading and loading of consumables.3
Specimens for both transcription-mediated amplification (TMA) and real-time transcription-mediated amplification (RT-TMA) assays can be loaded and run simultaneously on the same instrument.
RT-TMA assays:
Aptima HIV Quant Dx Assay, Aptima HCV Quant Dx Assay, and Aptima HBV Quant Assay use a process called (RT-TMA) to identify and quantitate pathogens.
Time to first result = 2.7 hours for the first five results. Five more results delivered every five minutes until the run is complete.
Maximum Throughput = 320 samples per 8 hours
TMA assays:
Aptima HPV Assay, Aptima HPV GT Assay, and Aptima Combo 2 Assay use transcription-mediated amplification (TMA) to detect pathogens.
Time to first result = 3.5 hours for the first five results. Five more results delivered every five minutes until the run is complete.
Maximum Throughput = 275 samples per 8 hours.
Hologic’s Panther System uses ordinary bleach to denature reagents, allowing for liquid waste to be disposed into the drain in accordance with local guidelines. There is no toxic guanidinium thiocyanate (GTC) waste associated with the Panther system.
The International Commercial Term, or Incoterm, associated with the all-inclusive testing price is DAP to the testing site or alternative site as reasonably requested by the customer (Incoterms 2020). When the order is placed, the customer may request that reagents and consumables be delivered directly to the central medical storage facility so long as proper cold chain capacity exists within the national supply chain to protect the integrity of the product during the shipment process.
The Aptima HIV Quant Dx assay, Aptima HCV Quant Dx assay, Aptima HBV Quant assay, Aptima HPV assay, Aptima Combo 2 assay (for CT/NG), Aptima SARS-CoV-2 assay, and ThinPrep Pap test vial (PreservCyt solution) are all CE marked and FDA approved. Additional in-country approval or registration may also be required in certain instances before these products would be available for shipment to certain eligible countries.
The Aptima HIV Quant Dx assay is WHO prequalified, including for DBS samples. The Aptima HCV Quant Dx assay and Aptima HPV assay have been submitted for WHO prequalification.
The Aptima HIV Quant Dx assay, Aptima HCV Quant Dx assay, Aptima HBV Quant assay, and Aptima SARS-CoV-2 assay are meet Global Fund’s quality assurance policy for In Vitro Diagnostics and are available for procurement.
Yes, the all-inclusive testing price includes Hologic’s Aptima DBS Extraction Buffer for use with the Aptima HIV Quant Dx assay for HIV testing. The price does not include DBS cards.
We’re all in this together.
We cross borders and break barriers to build a future of healthcare access for all. But we can’t do it alone. Learn more about what a partnership with the Global Access Initiative can mean for your community.
1. Data on file 2. USAID Global Health Supply Chain Program. Annual Report Fiscal Year 2024. ghsupplychain.org. Accessed February 13, 2026. https://www.ghsupplychain.org/sites/default/files/2025-09/GHSC-PSM%20FY24%20Q4_Annual%20Report-Final-remediated%20July14.pdf 3. PEPFAR supports a scale-up of HIV viral load testing through global, all inclusive, awards to Abbott, Hologic and Roche. USAID Global Health Supply Chain Program. October 27, 2020. Accessed October 13, 2025. https://www.ghsupplychain.org/news/viral-load-diagnostics 4. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. WHO. July 18, 2022. Accessed October 13, 2025. https://www.who.int/publications/i/item/9789240053779 5. Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020 Jul;40(5):602-608. doi: 10.1080/01443615.2019.1634030 6. WHO releases new estimates of the global burden of cervical cancer associated with HIV. WHO. November 16, 2020. Accessed October 13, 2025. https://www.who.int/news/item/16-11-2020-who-releases-new-estimates-of-the-global-burden-of-cervical-cancer-associated-with-hiv